Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas

European Journal of Pharmacology

Volumn 469, Issue 1-3, 2003, Pages 195-200

  Silvestre, Ramona A ^a   Rodríguez Gallardo, Jovita ^a   Egido, Eva M ^a   Marco, J ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Exendin 4; Glucagon; Insulin; Somatostatin

Indexed keywords

ANTIDIABETIC AGENT; ARGININE; EXENDIN 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; GLUCAGON RELEASE; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS PERFUSION; PARACRINE SIGNALING; PRIORITY JOURNAL; RAT; SOMATOSTATIN RELEASE;

EID: 0038392420     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01692-3     Document Type: Article

References (34)

1. Baron A., Fineman M., Young A., Gaines E., Prickett K. Synthetic exendin-4 (AC2993) reduces post-prandial glycemia, glucagon levels and slows gastric emptying in subjects with type 2 diabetes. Diabetologia. 43:2000;A190.
2. Chen Y.E., Drucker D.J. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin in the lizard. J. Biol. Chem. 272:1997;4108-4115.
3. Chepurny O.G., Hussain M.A., Holz G.G. Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. Endocrinology. 143:2002;2303-2313.
4. Creutzfeldt W. The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes. 109:2001;S288-S303.
5. D'Alessio D.A., Fujimoto W.Y., Ensinck J.W. Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes. 38:1989;1534-1538.
6. Drucker D.J. Glucagon-like peptides. Diabetes. 47:1998;159-169.
7. Egan J.M., Clocquet A.R., Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 87:2002;1282-1290.
8. Eissele R., Bothe-Sandfort E., Göke B., Eng J., Arnold R., Koop H. Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci. 55:1994;629-634.
9. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267:1992;7402-7405.
10. Faloona G.R., Unger R.H. Glucagon. Jaffe B.M., Behrman H.R. Methods of Hormone Radioimmunoassay. 1974;317-330 New York Academic, New York.
11. Gedulin B., Jodka L., Hoyt J. Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats. Diabetes. 48:1999;A199.
12. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268:1993;19650-19655.
13. Greig N.H., Holloway H.W., De Ore K.A., Jani D., Wang Y., Zhou J., Garant M.J., Egan J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 42:1999;45-50.
14. Harris V., Conlon J.M., Srikant C.B., McCorkle K., Schusdziarra V., Ipp E., Unger R.H. Measurements of somatostatin-like immunoreactivity in plasma. Clin. Chim. Acta. 87:1978;275-283.
15. Herbert V., Lau K.S., Gottlieb C.W., Bleicher S.J. Coated charcoal immunoassay of insulin. J. Clin. Endocrinol. Metab. 25:1965;1375-1384.
16. Kawai K., Suzuki S., Ohashi S., Mukai H., Ohmori H., Murayama Y., Yamashita J. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology. 124:1989;1768-1773.
17. Kolterman O., Gottlieb A., Prickett K., Gaines E., Young A. Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes. Diabetes. 49:2000;A114.
18. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., Tarui S. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes. 38:1989;902-905.
19. Leclercq-Meyer V., Marchand J., Leclercq R., Malaisse W.J. Glucagon and insulin release by the in vitro perfused rat pancreas. Diabete Metab. 2:1976;57-65.
20. Matschinsky F.M., Rujanavech C., Pagliara A., Norfleet W.T. Adaptations of α- and β-cells of rat and mouse pancreatic islets to starvation, to refeeding after starvation, and to obesity. J. Clin. Invest. 65:1980;207-218.
21. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 35:1992;701-711.
22. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 50:2001;583-589.
23. Parkes D.G., Gedulin B., Smith P., Young A. Effect of exendin-4 on glucagon secretion in lean and obese Zucker (ZDF) rats. Diabetes. 50:2001;A313.
24. Pipeleers D.G., Schuit F.C., Van Schravendijk C.F., Van de Winkel M. Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology. 117:1985;817-823.
25. Rodríguez-Gallardo J., Silvestre R.A., Egido E.M., Marco J. Insulin secretory pattern induced by exendin-4. Study in the perfused rat pancreas. Diabetologia. 43:2000;A138.
26. Rodríguez-Gallardo J., Egido E.M., Gutiérrez E., Garcia P., Silvestre R.A., Marco J. Evidence for a direct inhibitory effect of exendin-4 on alpha-cell secretion. Diabetologia. 45:2002;A214.
27. Samols E., Weir G.C., Bonner-Weir S. Intraislet insulin-glucagon-somatostatin relationships. Lefèbvre P.J. Handbook of Experimental Pharmacology: Glucagon. vol. 2:1983;133-173 Springer, Berlin.
28. Siegel S. Non Parametric Statistic for the Behavioral Changes. 1978;McGraw-Hill, New York.
29. Silvestre R.A., Miralles P., Moreno P., Villanueva M.L., Marco J. Somatostatin, insulin and glucagon secretion by the perfused rat pancreas from the cysteamine-treated rats. Biochem. Biophys. Res. Commun. 134:1986;1291-1297.
30. Taborsky G.J. Evidence of a paracrine role for pancreatic somatostatin "in vivo" Am. J. Physiol. 245:1983;E598-E603.
31. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-I receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 42:1993;1678-1682.
32. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 51:2002;1443-1452.
33. Weir G.C., Mojsov S., Hendrick K., Habener J.F. Diabetes. 38:1989;338-342.
34. Yalow R.S., Bergson S.A. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 39:1960;1157-1175.